alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 31









CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002



I, Cameron King, Chief Executive Officer and Acting Chief Financial Officer, of RedCell Power Corporation, certify that:



I have reviewed this quarterly report on Form 10-QSB of RedCell Power Corporation;



Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report.



Based on my knowledge, the financial statements, and other financial information included in the report, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in the report.



I and the other certifying officers are responsible for establishing and maintaining disclosure controls and procedures for the Company.



I and the other certifying officers have designed such disclosure controls and procedures to ensure that material information is made known to us, particularly during the period in which the periodic report is being prepared.



I and the other certifying officers have evaluated the effectiveness of the Companys disclosure controls and procedures as of a date within 90 days prior to the filing date of this report; and



I and the other certifying officers have presented in this report our conclusions about the effectiveness of the disclosure controls and procedures based on the required evaluation as of that date.



I and the other certifying officers have disclosed to the Companys auditors and to the audit committee of the board of directors (or persons fulfilling the equivalent function):



(i)

all significant deficiencies in the design or operation of internal controls which could adversely affect the Companys ability to record, process, summarize and report financial data and have identified for the Companys auditors any material weaknesses in internal controls; and



(ii)

any fraud, whether or not material, that involves management or other employees who have a significant role in the Companys internal controls; and



I and the other certifying officers have indicated in this report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.





Dated: April 22, 2005





Cameron King

_____________________________________

Cameron King

Chief Executive Officer, Acting Chief Financial Officer

---
Prepared by MERRILL CORPORATION





Exhibit


10.1


 


 


STRAIGHT NOTE


 


 


 


	
  $300,000

  	
   

  	
  South
  El Monte, California

  	
  November
  15, 2001

  



 


 


                For
value received, Lee Pharmaceuticals promises to pay Mark DiSalvo or order, at
South El Monte, California the sum of THREE HUNDRED THOUSAND DOLLARS, with
interest from November 15, 2001, on unpaid principal at the rate of twenty (20)
per cent per annum; principal is payable monthly, commencing on December 25,
2001, with monthly principal payments of $10,000.  Interest shall be calculated on the basis of the unpaid principal
balance daily, based on a 365-day year, actual day month and payable
monthly.  Principal and interest shall
be payable in lawful money of the United States.  If action were instituted on this note, I promise to pay such sum
as the Court may fix as attorney's fees. 
This note is secured by the trademarks on the product brands Sayman®,
Cankaid®, and Medicone®.


 


 


 


	
  November 8, 2001

  	
   

  	
  RONALD
  G. LEE

  
	
  Date

  	
   

  	
  Lee Pharmaceuticals -
  Ronald G. Lee

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  November 8, 2001

  	
   

  	
  MICHAEL
  L. AGRESTI

  
	
  Date

  	
   

  	
  Lee Pharmaceuticals -
  Michael L. Agresti
#### SOUTHEASTERN FIDELITY INSURANCE COMPANY, Plaintiff-Appellants, v. INSURANCE COMPANY OF NORTH AMERICA, Defendants-Appellees.

No. 6253.

Court of Appeal of Louisiana, Third Circuit.

Feb. 6, 1978.

Rehearing Denied March 29, 1978.

*550Guillory, McGee & Mayeux by Robert K. Guillory, Eunice, for plaintiff-appellant-ap-pellee, Theotis F. LeJeune.

C. Brent Coreil, Ville Platte, for defendant-appellant-appellee, Danny Glenn La-fleur.

Brame, Bergstedt & Brame, Joe A. Brame, Lake Charles, for defendant-appellant, Zurich Ins. Co.

Davidson, Meaux, Sonnier & Roy, Edward O. Taulbee, IV, Lafayette, for defendants-appellees-appellants, Randall Molitar, et al.

Raggio, Farrar, Cappel & Chozen by Stephen A. Berniard, Jr., Lake Charles, for defendant-appellant, Danny G. Lafleur.

Young & Burson by Joe Ortego, Eunice, for plaintiff-appellee, Ivy Fruge Molitor.

Fusilier, Pucheu & Soileau by L. 0. Fusilier, Ville Platte, for plaintiff-appellant-ap-pellee.

John Larry Vidrine, Ville Platte, for defendant-appellee-appellant.

Jack C. Fruge, Ville Platte, for defendants-appellees, Willie Smith and Dixie Auto. Ins. Co.

Lewis & Lewis, James T. Guglielmo, Opelousas, for defendant-appellee.

Voorhies & Labbe, Patrick A. Juneau, Jr., Lafayette, for defendant-appellee, Western World Ins. Co.

Calvin E. Hardin, Jr., Baton Rouge, for defendant-appellee, Ins. Co. of North America.

Allen, Gooch & Bourgeois, Ltd., Arthur I. Robison and Michael Harson, Lafayette, for intervenor-appellant, Insurance Co. of La.

Before CULPEPPER, DOMENGEAUX and JOHNSON, JJ.

JOHNSON, Judge.

This is an appeal from a companion case consolidated for trial with *LeJeune v. Allstate Insurance Company,*356 So.2d 537, our Docket # 6252, decided this date.

This is a suit for property damages by Southeastern Fidelity Insurance Company, the collision carrier of the automobile owned by Ivy Molitor. As the evidence reveals, Randy Molitor, who has heretofore been held negligent in the causing of the damages, losses and injuries herein, was over the age of eighteen years at the time of this accident. The evidence also shows that he had borrowed this car to run some errands of his own. The Court has already held herein that his mother, with whom he resides, Ivy Molitor, was not responsible for the negligence of Randy Molitor. Under these circumstances, she is entitled to recover from Danny Glenn Lafleur, the driver of the other vehicle who was also held to be negligent herein. Ivy Molitor is also entitled to recover under the doctrine of re-spondeat superior from the corporation, Ar-doin’s of Mamou, Inc. and from the automobile liability insurer of the hearse Lafleur was driving, Insurance Company of North America.

For the above and foregoing reasons, and for the reasons assigned in the *LeJeune v. Allstate Insurance Company*case, 356 So.2d 537, our Docket No. 2652, the judgment of the trial court is affirmed at appellants’ costs.

AFFIRMED.
TECHNICAL REPORT DOCUMENTATION PAGE

**Form DOT F 1700.7 (8-72)**Reproduction of completed page authorized.
#### James THOMAS a/k/a Jesse Glen Thomas, Appellant, v. STATE of Florida, Appellee.

No. 69-505.

District Court of Appeal of Florida. Second District.

Jan. 9, 1970.

PER CURIAM.

Affirmed.
**EXHIBIT 23.2**

 

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

 

We consent to the incorporation by reference in the Registration Statement (Form S-3 No. 333-34362) pertaining to 1,750,000 shares of commonstock of Optical Sensors Incorporated, and in the Registration Statement (Form S-8 No. 333-04373) pertaining to the Optical Sensors Incorporated 1989 Omnibus Stock Option Plan and the Optical Sensors Incorporated 1993 Stock Option Plan, and in theRegistration Statement (Form S-8 No. 333-17493) pertaining to the Optical Sensors Incorporated Employee Stock Purchase Plan, and in the Registration Statement (Form SB-2 No. 333-71076) pertaining to 15,583,333 shares of common stock of OpticalSensors Incorporated, and in the Registration Statement (Form S-8 No. 333-71354) pertaining to the Optical Sensors Incorporated 1993 Stock Option Plan, and in the Registration Statement (Form S-8 No. 333-114359) pertaining to the 2003 Stock OptionPlan, of our report dated February 27, 2004, with respect to the financial statements of Optical Sensors Incorporated included in the Annual Report (Form 10-KSB) for the year ended December 31, 2004. 

 

/s/ Ernst & Young, LLP 

 

Minneapolis, Minnesota 

March 23, 2005****
254 La. 831

#### In re Arthur W. JONES applying for Writ of Habeas Corpus.

No. 50188.

Supreme Court of Louisiana.

Nov. 6, 1969.

In re: Arthur W. Jones applying for writ of habeas corpus.

Writ refused. Considering the return of the district attorney the application is insufficient to warrant the exercise of our supervisory jurisdiction.
[Federal Register Volume 62, Number 25 (Thursday, February 6, 1997)]
[Notices]
[Pages 5639-5640]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-2887]


-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institute of Neurological Disorders and Stroke, Division 
of Extramural Activities; Notice of Closed Meeting

    Pursuant to Section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meeting.

    Name of Committee: National Institute of Neurological Disorders 
and Stroke Special Emphasis Panel (Telephone Conference Call).
    Date: February 19, 1997.
    Time: 1:00 p.m.
    Place: National Institutes of Health, 7550 Wisconsin Avenue, 
Room 9C10, Bethesda, Maryland 20892.
    Contact Person: Dr. Howard Weinstein/Mr. Phillip Wiethorn, 
Scientific Review Administrator, National Institutes of Health, 7550 
Wisconsin Avenue, Room 9C10, Bethesda, MD 20892, (301) 496-9223.
    Purpose/Agenda: To review and evaluate two SBIR Phase I Topic 
025 Contract Proposals.
    The meeting will be closed in accordance with the provisions set 
forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. 
Applications and/or proposals and the discussions could reveal 
confidential trade secrets or commercial property such as patentable 
material and personal information concerning individuals associated 
with the applications and/or proposals, the disclosure of which 
would constitute a clearly unwarranted invasion of personal privacy.


[[Page 5640]]


(Catalog of Federal Domestic Assistance Program No. 93.853, Clinical 
Research Related to Neurological Disorders; No. 93.854, Biological 
Basis Research in the Neurosciences)

    Dated: January 31, 1997.
Paula N. Hayes,
Acting Committee Management Officer, NIH.
[FR Doc. 97-2887 Filed 2-5-97; 8:45 am]
BILLING CODE 4140-01-M
No. 9637.

#### The United States Coal Co. *v.*Burriss et al.

(Decided December 21, 1906.)

Error to Circuit Court of Jefferson County.

*Messrs. Henderson, Quail & Siddall*and *Mr. A. C. Lewis,*for plaintiff in error.

*Mr. E. E. Erskine; Mr. J. W. Jordan*and *Mr. Dio Rogers*for defendants in error.

Judgment modified as shown in journal entry.

It is ordered and adjudged by this court, that the judgment of said circuit court be, and the same hereby is, modified so as to allow and permit plaintiff, the United States Coal Company, to erect and maintain upon and across the premises of defendants, or along the line of the premises of the defendants and the adjacent land-owners, such number of seiwice poles as shall be reasonably required for the proper support of the power transmitting wires of said coal company necessary to be used by said company in the proper and convenient mining by electricity of the coal now owned by it in Smithfield and Wells Townships, Jefferson County, Ohio. And it is ordered and adjudged by this court that this case be, and the same hereby is, remanded to the circuit .court of Jefferson county with instructions to that *617court to hear evidence and determine and establish a line upon or across the- premises in the petition described, or along the lines of the premises of the defendants and adjacent land-owners, upon which said poles may be erected and said wires may be strung, at such places and in such manner as will enable the coal company to properly, conveniently and economically carry on its business of mining as aforesaid, and as will not necessarily interfere with or impair the convenient use of defendants of their said premises. . .

Shauck, C. J., Price, Crew, Summers, Spear and Davis, JJ., concur.
1st Amend to Reg.'s Assoc. Stock Ownership Plan



 






Exhibit 10.10



First Amendment

to the

Associate Stock Ownership Plan







(Amended and Restated

as of December 31, 1997)







     Resolved, that the Associate Stock Ownership Plan (the “Plan”) amended and
restated as of December 31, 1997, is hereby amended in the following
particulars, effective as of January 1, 2001;





	 	1.	 	By deleting the last two
sentences in Section 2 Eligibility
and replacing them with the following:




	 	 	 	Further notwithstanding anything contained in the Plan to the
contrary, the maximum contributions that can be made by an Eligible
Employee during the calendar year shall not exceed the lessor of
(i) a number of Common shares, which when aggregated, would not
have a fair market value (as determined on the first day of the
applicable Purchase Periods) in excess of $25,000, and (ii) 15% of
the Eligible Employee’s compensation paid during the calendar year.
In addition, the number of Common Shares which may be purchased by
any Eligible Employee during the Purchase Period shall not exceed
1000, subject to adjustment in the same manner described in Section
12, in the case of the occurrence of any of the events described in
Section 12.




	 	2.	 	By deleting the percentage of 10% in the second sentence of
the second paragraph of subsection (a) Payroll Deduction of Section
4 Basis of Participation, and replacing it with 15%.
EASTERN FEDERAL LANDS ACCESS PROGRAM

Application 

Number Project/Facility Name Project Type Federal Land Unit Accessed Applicant County

WV-01 Lake Sherwood Road (CR14/1) Phase II Roadway Resurfacing

U.S. Forest Service - 

Monongahela National 

Forest

WV Division of 

Highways Greenbriar

WV-02 Piney Creek Trail Trail Construction

National Park Service - 

New River Gorge 

National River

Raleigh County 

Commission Raleigh

WV-03 Fayette Station Road Improvements 

(Phase I and II) Roadway Reconstruction

National Park Service - 

New River Gorge 

National River

WV Division of 

Highways Fayette

WV-05 County Road 35/18 Improvements Roadway Resurfacing

U.S. Fish & Wildlife 

Service - Canaan Valley 

National Wildlife 

Refuge

WV Division of 

Highways Tucker

WV-06 Potomac Street Improvements Roadway Reconstruction

National Park Service - 

Harpers Ferry National 

Historic Park

Town of Harpers 

Ferry

Jefferson

The Programming Decisions Committee (PDC) responsible for the West Virginia Federal Lands Access Program (FLAP) has selected its initial, multiyear 

Program of Projects. The projects identified for programming for the West Virginia FLAP are listed below in no particular order, and include:

West Virginia Program of Projects for Fiscal Years 2013-2014
EASTERN FEDERAL LANDS ACCESS PROGRAM

The next step in the process will be to develop project agreements between Eastern Federal Lands Highway Division and the State/Local Agency 

partners. The amount of funds allocated will depend on finalizing these agreements. Funding for these projects is not guaranteed. Funding beyond FY 

2014 is dependent on reauthorization of the Access Program by Congress. The West Virginia PDC does not have a firm date for the next call for projects 

under the Access Program, but another call is anticipated within the next year. If you have any questions please contact David Payne, Access Program 

Manager, at 571-434-1543 or email at David.Payne@dot.gov.
255 La. 485

#### MEYNIER AND DILLMAN HARDWARE COMPANY, Inc. v. Bernard J. ARONSON etc., et al. Bernard J. ARONSON and Gulf Insurance Co. v. Percy BIAS and Meynier and Dillman Hardware Company, Inc.

No. 50385.

Supreme Court of Louisiana.

Feb. 27, 1970.

In re: Bernard J. Aronson, Individually and as Administrator of the Estate of the Minor, Jan E. Aronson, and Gulf Insurance Company applying for certiorari, or writ of review, to the Court of Appeal, Fourth Circuit, Parish of Orleans. 229 So. 2d 365.

Writ refused. On the facts found by the Court of Appeal, there is no error in the judgment complained of.
II 

118TH CONGRESS 

1ST SESSION S. 3557 

To require the Secretary of Health and Human Services to prepare a report 

that outlines a plan for completing a review of approved opioid analgesic 

drugs that considers the public health effects of such opioid drugs. 

IN THE SENATE OF THE UNITED STATES 

DECEMBER 19, 2023 

Mr. MURPHY (for himself and Mr. BRAUN) introduced the following bill; which 

was read twice and referred to the Committee on Health, Education, 

Labor, and Pensions 

A BILL 

To require the Secretary of Health and Human Services 

to prepare a report that outlines a plan for completing 

a review of approved opioid analgesic drugs that considers the public health effects of such opioid drugs. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. REVIEW OF OPIOID DRUGS AND ACTIONS. 

4 Not later than one year after the date of enactment 

5 of this Act, the Secretary of Health and Human Services 

6 (referred to in this section as the ‘‘Secretary’’) shall pub7 lish on the website of the Food and Drug Administration 

8 (referred to in this section as the ‘‘FDA’’) a report that 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•S 3557 IS

1 outlines a plan for completing a review of opioid analgesic 

2 drugs that are approved under section 505 of the Federal 

3 Food, Drug, and Cosmetic Act (21 U.S.C. 355) that con4 siders the public health effects of such opioid drugs as part 

5 of the benefit-risk assessment, and that addresses the ac6 tivities of the FDA that relate to increasing the develop7 ment of non-addictive medical products intended to treat 

8 pain or addiction. Such report shall include— 

9 (1) an opportunity for public input concerning 

10 the regulation by the FDA of opioid analgesic drugs, 

11 including scientific evidence that relates to condi12 tions of use, safety, or benefit-risk assessment (in13 cluding consideration of the public health effects) of 

14 such opioid drugs; 

15 (2) an update on the actions taken by the FDA 

16 to review the effectiveness, safety, benefit-risk profile 

17 (which may include public health effects), and use of 

18 approved opioid analgesic drugs; 

19 (3) a timeline for an assessment of the potential 

20 need, as appropriate, for labeling changes, revised or 

21 additional postmarketing requirements, enforcement 

22 actions, or withdrawals for opioid analgesic drugs; 

23 (4) an overview of the steps that the FDA has 

24 taken to support the development and approval of 

25 non-addictive medical products intended to treat 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
3 

•S 3557 IS

1 pain or addiction, and actions planned to further 

2 support the development and approval of such prod3 ucts; and 

4 (5) an overview of the consideration by the 

5 FDA of clinical trial methodologies for analgesic 

6 drugs, including the enriched enrollment randomized 

7 withdrawal methodology, and the benefits and draw8 backs associated with different trial methodologies 

9 for such drugs, incorporating any public input re10 ceived under paragraph (1). 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
### Regulato ry Evalu ation

Docket No. FAA- Dir ectorate Ident i fier: 

### -AD 

## if

you make changes to the va lues in the table below, you must ensure the totals update accordingly. 

## if they do not, click (or Tab) into and then out of th e changed cell

. Est im ated 

### Costs: Action Costs per Product (e.g., aircraft, eng ine, (e.g., In spection, propeller, appliance) Work-hours Labor Parts Cost Total Costs Number of Total Cost replacement) (include cost (labor+ 

## u.s. for U.S. Fleet Do not include onco ndition costs here acces s, testing, (@$85/h parts) Registered and close-up) o ur) Prod ucts 

### Same as ex i sti n g action '

II



### '
' 

# .

I

The known number of products in comp l iance : Total Costs of compliance for 

### U.S. fl eet: $ 0 Costs covered under warranty (if known) $
On-Condition 

### Co sts : • Action Work-hours Labor cost Parts Cost Cost per Product (e.g., Inspection, (include access, (@$85/hour)

replacement) testing, and closeup)



### Special considerations for Eco nomic Analysis (Use thisfield t o explain an ythi ng in th e Estimated Costs table that was assumed or might n ot be obv ious. This field can also be used to explain warranty costs):

### Executive Order 12866: Could the AD be considered a "significant regulatory action"?

# ~ YES* D**NO~** 

### *Explanation: 

### DOT Regulatory Policies and Procedures: Is the AD significant?

# ~ YES*0**NO~** 

### *Explanation: 

### Regulatory Flexibility Act: Will the AD have a significant economic impact on a substantial number of small entities? Explain for either a Yes or No answer.

# · YESD**NO~** 

### Explanation: 

### Intrastate Aviation in Alaska: This AD could affect intrastate aviation in Alaska. Is it appropriate to include specific requirements for aircraft operated in Alaska where aviation might be the only mode of transportation?

# ~ YES*0**NO~** 

### *Explanation:
Incorporation by Reference 

Docket ID No. EPA-HQ-OAR-2010-0560 

July 8, 2010 

The contents of the following dockets are hereby incorporated by reference into and are 

considered to be included in, contained in and to have been placed in Docket EPA-HQ-OAR2010-0560 (Call for Information: Information on GHG Emissions from Bioenergy and Other 

Biogenic Sources): 

1) EPA-HQ-OAR-2008-0508 (Greenhouse Gas Reporting Program) 

2) EPA-HQ-OAR-2009-0517 (Prevention of Significant Deterioration and Title V 

Greenhouse Gas Tailoring Rule) 

3) EPA- HQ–OAR–2005–0161 (Regulation of Fuels and Fuel Additives: Renewable Fuel 

Program) 

Accessing dockets: 

Publicly available docket materials are available either electronically through 

www.regulations.gov or in hard copy at EPA’s Docket Center, Public Reading Room, EPA West 

Building, Room 3334, 1301 Constitution Avenue, NW, Washington, DC 20004. This Docket 

Facility is open from 8:30 a.m. to 4:30 p.m., Monday through Friday, excluding legal holidays. 

The telephone number for the Public Reading Room is (202) 566-1744, and the telephone 

number for the Air Docket is (202) 566-1742.